A/Prof. Gauri Rao (USA)
A/Prof. Gauri Rao is an Associate Professor at the University of Southern California and the Director for the Center for Quantitative Drug and Disease Modeling. A/Prof. Rao earned her PharmD from the University of Buffalo. She completed her postdoctoral training in Infectious diseases Pharmacokinetics/Pharmacodynamics (PK/PD) with a Masters in Pharmacometrics at the University at Buffalo in collaboration with Hoffmann La Roche.
Her translational research program focuses on using a systems-based approach to study the dynamic interplay between host immune response, antibiotic treatment, and bacterial resistance mechanisms to determine its impact on disease progression and biomarker response. She has applied innovative quantitative approaches for designing optimized antibiotic as well as phage treatment regimens.
A/Prof. Rao’s innovative work focused on addressing antimicrobial resistance has been supported by National Institutes of Health (NIH), Department of Defense (DOD), Food and Drug Administration (FDA) and Cystic Fibrosis Foundation (CFF). A/Prof. Rao is the 2023 Leon I. Goldberg Early Investigator Award recipient, which recognizes and honors young scientists for outstanding accomplishments in the field of clinical pharmacology achieved early in their careers.
A/Prof. Gauri Rao is an Associate Professor at the University of Southern California and the Director for the Center for Quantitative Drug and Disease Modeling. A/Prof. Rao earned her PharmD from the University of Buffalo. She completed her postdoctoral training in Infectious diseases Pharmacokinetics/Pharmacodynamics (PK/PD) with a Masters in Pharmacometrics at the University at Buffalo in collaboration with Hoffmann La Roche.
Her translational research program focuses on using a systems-based approach to study the dynamic interplay between host immune response, antibiotic treatment, and bacterial resistance mechanisms to determine its impact on disease progression and biomarker response. She has applied innovative quantitative approaches for designing optimized antibiotic as well as phage treatment regimens.
A/Prof. Rao’s innovative work focused on addressing antimicrobial resistance has been supported by National Institutes of Health (NIH), Department of Defense (DOD), Food and Drug Administration (FDA) and Cystic Fibrosis Foundation (CFF). A/Prof. Rao is the 2023 Leon I. Goldberg Early Investigator Award recipient, which recognizes and honors young scientists for outstanding accomplishments in the field of clinical pharmacology achieved early in their careers.